Since the pathophysiology of hypertension has made greatadvances during the past years, the underlying physiological derangementin individual patients with hypertension can be more accuratelyexplained and treatment can be targeted at the pathophysiology of theindividual patient.
Research over the past years has indicated that there is significantevidence that endothelin, endothelium derived relaxing factor (EDRF) andbiogenic amines, especially 5HT2 receptor antagonists are involved inthe regulation, development and maintenance of cardiovascularhypertension in both central and peripheral sites. Moreover, it has beenreported that ouabain (g-strophanthin) might be the endogenousdigitalis-like substance. This endogenous digitalis-like substance mightincrease arterial tone, total peripheral resistance and, finally, onsethypertension. These advances in pathophysiology of hypertension havebeen the driving force for the development of new antihypertensivedrugs.
This volume summarizes the recent advances in basic and clinicalresearch dedicated to new antihypertensive drugs and describes relatedinteractions. The book will be of value and interest to those involvedin the field of hypertension as well researchers in neurosciences andpharmacology.
1992; xii+376 pages ISBN 90-6764-140-5 Price (all prices are subject to change without notice): EUR 133/US$ 190
